BioMarin Pharma (BMRN) Tops Q3 EPS by 20c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $69.25 +3.37%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of $0.12, $0.20 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $776 million versus the consensus estimate of $782.3 million.
GUIDANCE:
BioMarin Pharma sees FY2025 EPS of $4.40-$4.55, versus the consensus of $3.34. BioMarin Pharma sees FY2025 revenue of $3.15-3.2 billion, versus the consensus of $3.17 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FOMC minutes from July 28-29th meeting
- Scorpion Capital says short Twist Biosciences
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
